An investor has shown a strong commitment to Core Scientific, a digital asset mining and blockchain infrastructure company, as they pivot their business strategy. Valiant Capital Management, based in San Francisco, increased its stake in Core Scientific by acquiring an additional 1.68 million shares during the third quarter of the year. This transaction, detailed in a Securities and Exchange Commission (SEC) filing on November 14, enhanced Valiant’s total holdings to approximately 6.48 million shares, representing a market value of around $116.31 million as of September 30. The firm also holds call options linked to roughly 4.21 million shares.
As of the latest filing, Valiant’s primary investments include Core Scientific, making up about 10.8% of their assets under management (AUM), alongside other significant positions in indices like the S&P 500 and Russell 2000, as well as specific stocks such as AGX and GEV.
Currently, Core Scientific shares are priced at $14.65, marking a modest increase of about 4% over the past year. However, this has been overshadowed by the S&P 500’s stronger performance, which has risen by approximately 17% in the same period.
Core Scientific operates a dual business model that includes both self-mining of digital assets and providing colocation services to large-scale miners and blockchain firms. The company features large-scale data centers, generating income through its mining operations and hosting solutions. However, the company has faced challenges, reporting a net income loss of approximately $768.31 million.
Despite a recent downturn in share prices—about a 32% decline after the announcement of a proposed merger with CoreWeave was scrapped—the optimistic stance taken by Valiant signals confidence in Core Scientific’s future prospects. The initial rise in share value earlier in the year—roughly 24%—reflected increasing market optimism regarding infrastructure monetization and the company’s strategic focus.
Analysts suggest that Valiant’s investment may not merely be a response to the market’s volatility, as their increased stake was established during a time of rising share prices, indicating a deliberate endorsement of Core Scientific’s evolving business strategy and potential for growth amidst uncertainty. As Valiant maintains the most concentrated position in its portfolio with Core Scientific, it reflects a willingness to accept volatility for the chance of significant returns.
